VKTX
Viking Therapeutics, Inc.
Biotechnology
Market Cap$3.63B
5Y Perf.+184.4%
Compare Stocks
5 / 10Try these comparisons:
Stock Comparison
VKTX vs TERN vs PEPG vs KYMR vs GPCR
Revenue, margins, valuation, and 5-year total return — side by side.
TERN
Terns Pharmaceuticals, Inc.
Biotechnology
Market Cap$4.64B
5Y Perf.+422.5%
PEPG
PepGen Inc.
Biotechnology
Market Cap$133M
5Y Perf.-87.4%
KYMR
Kymera Therapeutics, Inc.
Biotechnology
Market Cap$6.75B
5Y Perf.+163.6%
GPCR
Structure Therapeutics Inc.
Biotechnology
Market Cap$2.37B
5Y Perf.+60.8%
VKTX vs TERN vs PEPG vs KYMR vs GPCR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | VKTX | TERN | PEPG | KYMR | GPCR |
|---|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $3.63B | $4.64B | $133M | $6.75B | $2.37B |
| Revenue (TTM) | $0.00 | $0.00 | $0.00 | $51M | $0.00 |
| Net Income (TTM) | $-472M | $-94M | $-90M | $-315M | $-141M |
| Gross Margin | — | — | — | 33.2% | — |
| Operating Margin | — | — | — | -7.0% | — |
| Total Debt | $137K | $1M | $17M | $82M | $6M |
| Cash & Equiv. | $166M | $161M | $61M | $357M | $800M |
VKTX vs TERN vs PEPG vs KYMR vs GPCR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
VKTX
TERN
PEPG
KYMR
GPCR
| Stock | Feb 23 | May 26 | Return |
|---|---|---|---|
| Viking Therapeutics… (VKTX) | 100 | 284.4 | +184.4% |
| Terns Pharmaceutica… (TERN) | 100 | 522.5 | +422.5% |
| PepGen Inc. (PEPG) | 100 | 12.6 | -87.4% |
| Kymera Therapeutics… (KYMR) | 100 | 263.6 | +163.6% |
| Structure Therapeut… (GPCR) | 100 | 160.8 | +60.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VKTX vs TERN vs PEPG vs KYMR vs GPCR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: PEPG leads in 2 of 6 categories (5-stock set), making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. Viking Therapeutics, Inc. is the stronger pick specifically for profitability and margin quality. TERN and GPCR also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
VKTX
Viking Therapeutics, Inc.
The Long-Run Compounder
VKTX is the #2 pick in this set and the best alternative if long-term compounding is your priority.
- 24.0% 10Y total return vs TERN's 188.0%
- 4.7% margin vs KYMR's -6.1%
Best for: long-term compounding
TERN
Terns Pharmaceuticals, Inc.
The Defensive Pick
TERN ranks third and is worth considering specifically for sleep-well-at-night.
- Lower volatility, beta 0.39, Low D/E 0.4%, current ratio 23.14x
- +15.1% vs VKTX's +6.2%
Best for: sleep-well-at-night
PEPG
PepGen Inc.
The Income Pick
PEPG carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.17
- EPS growth 25.6%
- Beta 0.17, current ratio 11.94x
- -1.0% revenue growth vs VKTX's -270.1%
Best for: income & stability and growth exposure
KYMR
Kymera Therapeutics, Inc.
The Healthcare Pick
Among these 5 stocks, KYMR doesn't own a clear edge in any measured category.
Best for: healthcare exposure
GPCR
Structure Therapeutics Inc.
The Niche Pick
GPCR is the clearest fit if your priority is efficiency.
- -13.8% ROA vs VKTX's -65.3%, ROIC -30.3% vs -44.4%
Best for: efficiency
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | PEPG | -1.0% revenue growth vs VKTX's -270.1% |
| Quality / Margins | VKTX | 4.7% margin vs KYMR's -6.1% |
| Stability / Safety | PEPG | Beta 0.17 vs VKTX's 1.61 |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | TERN | +15.1% vs VKTX's +6.2% |
| Efficiency (ROA) | GPCR | -13.8% ROA vs VKTX's -65.3%, ROIC -30.3% vs -44.4% |
VKTX vs TERN vs PEPG vs KYMR vs GPCR — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLGPCRLAGGINGKYMR
Who Leads Where
GPCR leads in 2 of 6 categories
TERN leads 1 • VKTX leads 0 • PEPG leads 0 • KYMR leads 0 • 2 tied
Explore the data ↓KYMRKymera Therapeutics, …
0leads
PEPGPepGen Inc.
0leads
VKTXViking Therapeutics, …
0leads
TERNTerns Pharmaceuticals…
1leads
GPCRStructure Therapeutic…
2leads
6 Total Categories
CATEGORYLEADERvs TERNvs VKTXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
GPCR1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
GPCR4/9
Total Returns1Y, 3Y, 5Y total returns with dividends
TERN4/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
GPCR leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
KYMR and GPCR operate at a comparable scale, with $51M and $0 in trailing revenue.
| Metric | VKTXViking Therapeuti… | TERNTerns Pharmaceuti… | PEPGPepGen Inc. | KYMRKymera Therapeuti… | GPCRStructure Therape… |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $0 | $0 | $51M | $0 |
| EBITDAEarnings before interest/tax | -$502M | -$108M | -$90M | -$352M | -$175M |
| Net IncomeAfter-tax profit | -$472M | -$94M | -$90M | -$315M | -$141M |
| Free Cash FlowCash after capex | -$340M | -$78M | -$82M | -$244M | -$226M |
| Gross MarginGross profit ÷ Revenue | — | — | — | +33.2% | — |
| Operating MarginEBIT ÷ Revenue | — | — | — | -7.0% | — |
| Net MarginNet income ÷ Revenue | — | — | — | -6.1% | — |
| FCF MarginFCF ÷ Revenue | — | — | — | -4.7% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — | — | +55.5% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -2.3% | +3.6% | +60.3% | +13.4% | +195.2% |
GPCR leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — TERN and PEPG each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | VKTXViking Therapeuti… | TERNTerns Pharmaceuti… | PEPGPepGen Inc. | KYMRKymera Therapeuti… | GPCRStructure Therape… |
|---|---|---|---|---|---|
| Market CapShares × price | $3.6B | $4.6B | $133M | $6.8B | $2.4B |
| Enterprise ValueMkt cap + debt − cash | $3.5B | $4.5B | $89M | $6.5B | $1.6B |
| Trailing P/EPrice ÷ TTM EPS | -9.81x | -47.29x | -0.91x | -22.41x | -17.13x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — | — | 172.26x | — |
| Price / BookPrice ÷ Book value/share | 5.52x | 12.18x | 0.55x | 4.42x | 1.60x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | — |
Evenly matched — TERN and PEPG each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
GPCR leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
GPCR delivers a -14.5% return on equity — every $100 of shareholder capital generates $-15 in annual profit, vs $-76 for PEPG. VKTX carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to PEPG's 0.12x. On the Piotroski fundamental quality scale (0–9), PEPG scores 4/9 vs VKTX's 2/9, reflecting mixed financial health.
| Metric | VKTXViking Therapeuti… | TERNTerns Pharmaceuti… | PEPGPepGen Inc. | KYMRKymera Therapeuti… | GPCRStructure Therape… |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -71.3% | -30.0% | -75.7% | -25.0% | -14.5% |
| ROA (TTM)Return on assets | -65.3% | -28.5% | -60.4% | -22.3% | -13.8% |
| ROICReturn on invested capital | -44.4% | -42.2% | -73.2% | -24.9% | -30.3% |
| ROCEReturn on capital employed | -51.8% | -33.7% | -63.4% | -27.2% | -24.1% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 3 | 4 | 4 | 3 |
| Debt / EquityFinancial leverage | 0.00x | 0.00x | 0.12x | 0.05x | 0.00x |
| Net DebtTotal debt minus cash | -$166M | -$160M | -$44M | -$275M | -$793M |
| Cash & Equiv.Liquid assets | $166M | $161M | $61M | $357M | $800M |
| Total DebtShort + long-term debt | $137,000 | $1M | $17M | $82M | $6M |
| Interest CoverageEBIT ÷ Interest expense | -15687.44x | — | — | -2119.53x | — |
GPCR leads this category, winning 4 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
TERN leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in VKTX five years ago would be worth $52,710 today (with dividends reinvested), compared to $1,497 for PEPG. Over the past 12 months, TERN leads with a +1505.1% total return vs VKTX's +6.2%. The 3-year compound annual growth rate (CAGR) favors TERN at 62.0% vs PEPG's -49.4% — a key indicator of consistent wealth creation.
| Metric | VKTXViking Therapeuti… | TERNTerns Pharmaceuti… | PEPGPepGen Inc. | KYMRKymera Therapeuti… | GPCRStructure Therape… |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -11.6% | +32.1% | -73.1% | +13.7% | -39.7% |
| 1-Year ReturnPast 12 months | +6.2% | +1505.1% | +34.0% | +146.3% | +49.2% |
| 3-Year ReturnCumulative with dividends | +37.0% | +325.1% | -87.1% | +185.1% | +73.8% |
| 5-Year ReturnCumulative with dividends | +427.1% | +210.7% | -85.0% | +100.6% | +58.1% |
| 10-Year ReturnCumulative with dividends | +2404.8% | +188.0% | -85.0% | +148.7% | +58.1% |
| CAGR (3Y)Annualised 3-year return | +11.1% | +62.0% | -49.4% | +41.8% | +20.2% |
TERN leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
Evenly matched — TERN and PEPG each lead in 1 of 2 comparable metrics.
Risk & Volatility
PEPG is the less volatile stock with a 0.17 beta — it tends to amplify market swings less than VKTX's 1.61 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. TERN currently trades 99.6% from its 52-week high vs PEPG's 24.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | VKTXViking Therapeuti… | TERNTerns Pharmaceuti… | PEPGPepGen Inc. | KYMRKymera Therapeuti… | GPCRStructure Therape… |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.61x | 0.39x | 0.17x | 1.15x | 0.96x |
| 52-Week HighHighest price in past year | $43.15 | $53.18 | $7.80 | $103.00 | $94.90 |
| 52-Week LowLowest price in past year | $22.96 | $2.66 | $1.01 | $28.06 | $15.80 |
| % of 52W HighCurrent price vs 52-week peak | +72.6% | +99.6% | +24.7% | +80.3% | +43.3% |
| RSI (14)Momentum oscillator 0–100 | 43.9 | 73.9 | 34.5 | 48.2 | 34.1 |
| Avg Volume (50D)Average daily shares traded | 2.3M | 6.6M | 1.5M | 623K | 945K |
Evenly matched — TERN and PEPG each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: VKTX as "Buy", TERN as "Buy", PEPG as "Buy", KYMR as "Buy", GPCR as "Buy". Consensus price targets imply 262.7% upside for PEPG (target: $7) vs 4.9% for TERN (target: $56).
| Metric | VKTXViking Therapeuti… | TERNTerns Pharmaceuti… | PEPGPepGen Inc. | KYMRKymera Therapeuti… | GPCRStructure Therape… |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $100.75 | $55.56 | $7.00 | $117.06 | $114.75 |
| # AnalystsCovering analysts | 24 | 16 | 6 | 26 | 14 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
GPCR leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). TERN leads in 1 (Total Returns). 2 tied.
Best OverallStructure Therapeutics Inc. (GPCR)Leads 2 of 6 categories
Loading custom metrics...
VKTX vs TERN vs PEPG vs KYMR vs GPCR: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is VKTX or TERN or PEPG or KYMR or GPCR a better buy right now?
Analysts rate Viking Therapeutics, Inc.
(VKTX) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — VKTX or TERN or PEPG or KYMR or GPCR?
Over the past 5 years, Viking Therapeutics, Inc.
(VKTX) delivered a total return of +427. 1%, compared to -85. 0% for PepGen Inc. (PEPG). Over 10 years, the gap is even starker: VKTX returned +24. 0% versus PEPG's -85. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — VKTX or TERN or PEPG or KYMR or GPCR?
By beta (market sensitivity over 5 years), PepGen Inc.
(PEPG) is the lower-risk stock at 0. 17β versus Viking Therapeutics, Inc. 's 1. 61β — meaning VKTX is approximately 829% more volatile than PEPG relative to the S&P 500. On balance sheet safety, Viking Therapeutics, Inc. (VKTX) carries a lower debt/equity ratio of 0% versus 12% for PepGen Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — VKTX or TERN or PEPG or KYMR or GPCR?
On earnings-per-share growth, the picture is similar: PepGen Inc.
grew EPS 25. 6% year-over-year, compared to -215. 8% for Viking Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — VKTX or TERN or PEPG or KYMR or GPCR?
Viking Therapeutics, Inc.
(VKTX) is the more profitable company, earning 0. 0% net margin versus -794. 4% for Kymera Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VKTX leads at 0. 0% versus -891. 3% for KYMR. At the gross margin level — before operating expenses — KYMR leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — VKTX or TERN or PEPG or KYMR or GPCR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is VKTX or TERN or PEPG or KYMR or GPCR better for a retirement portfolio?
For long-horizon retirement investors, PepGen Inc.
(PEPG) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 17)). Viking Therapeutics, Inc. (VKTX) carries a higher beta of 1. 61 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PEPG: -85. 0%, VKTX: +24. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between VKTX and TERN and PEPG and KYMR and GPCR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.